Reliability, Validity, and Responsiveness of the Six-minute Walk Test in Patients with Heart Failure.

Demers, Catherine; McKelvie, Robert S.; Negassa, A.; Yusuf, S.

doi:10.1097/01823246-200213030-00004

Cited by 14 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Assessing the 4-m walking speed alone has already been demonstrated to be comparable to performing the full Established Population for Epidemiological Studies of the Elderly physical performance battery. 1 The 4-m walk test has also shown sufficient reliability, 13,25 and its test-retest reliability was also high in this study, as reflected by an intraclass r40.9.…”

Section: Discussionsupporting

confidence: 48%

“…12 The 6-minute walk test has proven to be highly reliable. [13][14][15][16][17] It is frequently used to assess functional capacity or severity of dyspnea in chronic cardiopulmonary disorders, 18,19 it is often used to evaluate endurance 19 and effect of exercise training, 20 and it is a good measure of overall functional status in elderly adults. 21 During this test, participants are encouraged to walk at a regular pace for as great a distance as possible over a 6-minute period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reliability of the 400‐M Usual‐Pace Walk Test as an Assessment of Mobility Limitation in Older Adults

Rolland

Cesari

Miller

et al. 2004

J American Geriatrics Society

165

114

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Reliability of the 400‐M Usual‐Pace Walk Test as an Assessment of Mobility Limitation in Older Adults

Rolland

Cesari

Miller

et al. 2004

J American Geriatrics Society

165

114

View full text Add to dashboard Cite

show abstract

“…Other reports indicate that the walked distance correlates with NYHA functional class and prognosis in HF. 10,11,30 In this study there was no significant difference in walked distance between groups of NYHA classes, possibly owing to the small sample size. However, the walked distance correlated with an increase of RVSP, RVDP, and ePAD achieved during the tests.…”

Section: Discussioncontrasting

confidence: 53%

“…3 -5 The six-minute walk test (6MWT) is widely used in routine practice and clinical trials 6 as a simple tool to assess functional capacity in HF patients and is thought to reflect the activity of daily living better than the evaluations at peak exercise. 7 -9 Furthermore, the distance covered during 6 min of walking has been shown to be highly reproducible, 10 correlate with patient symptoms, 10 and has been identified as an independent predictor of morbidity and survival in patients with left ventricular (LV) dysfunction. 11 However, it remains unclear, whether this 'snapshot picture' from an artificial laboratory test truly reflects the exercise levels a HF patient is exposed to during his activities of daily living.…”

Section: Introductionmentioning

confidence: 99%

Continuous central haemodynamic measurements during the six‐minute walk test and daily life in patients with chronic heart failure

Braunschweig

Linde

Adamson

et al. 2009

European J of Heart Fail

View full text Add to dashboard Cite

AimsTo compare haemodynamic responses during the 6-min walk test (6MWT) and daily living activities in heart failure (HF) patients. Methods and resultsEighteen HF patients received an implantable haemodynamic monitor, which continuously measured heart rate (HR), estimated pulmonary artery diastolic pressure (ePAD), and several right ventricular (RV) pressure parameters. During the 6MWT, haemodynamics were assessed at rest and peak exercise. Ambulatory values were measured as the daily minimum, maximum, and median, averaged over the 14-day period surrounding each 6MWT. During the 6MWT, HR increased from 71 + 17 to 101 + 20 b.p.m. and ePAD from 20 + 5 to 34 + 8 mmHg. Daily minimum values were significantly lower and daily maximum values higher compared with rest and peak exercise. Patients with a walked distance above the median (402 m) had lower resting HR (64 + 10 vs. 77 + 20, P ¼ 0.001) and ePAD (18 + 4 vs. 21 + 7, P ¼ 0.022) compared to patients with walked distances below the median; values at peak exercise were similar. This pattern was also observed during the ambulatory periods. ConclusionRanges of HR and RV pressures are significantly larger during daily living activities compared with 6MWT in HF patients. Haemodynamic characteristics of patients with greater exercise capacity include lower resting HR and RV pressures and are similar during the 6MWT and daily life.--

show abstract

“…However, this outcome measure, the change in PRP, has minimal clinical relevance and no known prognostic significance in patients with CHF. 26 On the other hand, the 6 min walk test distance is a surrogate measure that provides relevant information about death 27 and QOL, 28 arguably the two most clinically relevant outcome measures in heart failure. Further, peak VO 2 is an objective, reproducible measure of maximal functional capacity, and is a strong, consistent, and well-validated predictor of mortality in heart failure.…”

Section: Discussionmentioning

confidence: 99%

Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial

Zick

Vautaw

Gillespie

et al. 2009

European J of Heart Fail

View full text Add to dashboard Cite

Aims Hawthorn's efficacy when added to contemporary evidence‐based heart failure therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy. Methods and results We performed a randomized, double‐blind, placebo‐controlled trial in 120 ambulatory patients aged ≥18 years with New York Heart Association (NYHA) class II‐III chronic heart failure. All patients received conventional medical therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life (QOL) measures, peak oxygen consumption, and anaerobic threshold during maximal treadmill exercise testing, NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress and inflammation. There were no significant differences between groups in the change in 6 min walk distance (P = 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or inflammation. A modest difference in LVEF favoured hawthorn (P = 0.04). There were significantly more adverse events reported in the hawthorn group (P = 0.02), although most were non‐cardiac. Conclusion Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure. This trial is registered in http://ClinicalTrials.gov ID: NCT00343902.

show abstract

Reliability, Validity, and Responsiveness of the Six-minute Walk Test in Patients with Heart Failure.

Cited by 14 publications

References 0 publications

Reliability of the 400‐M Usual‐Pace Walk Test as an Assessment of Mobility Limitation in Older Adults

Reliability of the 400‐M Usual‐Pace Walk Test as an Assessment of Mobility Limitation in Older Adults

Continuous central haemodynamic measurements during the six‐minute walk test and daily life in patients with chronic heart failure

Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial

Contact Info

Product

Resources

About